Zenotech Laboratories Ltd Company Summary

Zenotech Laboratories Limited was initially established as Sunline Technologies Limited in June, 1989 and changed to the present name w.e.f. August 9, 2004. Company is a loan licensing company catering exclusively to Sun Pharmaceutical Industries Limited, Promoter & holding company and they are specialized contract manufacturing services /processing in parenteral depot formulations, ophthalmic, oncology oral & injectables and general injectables.

Companys injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology.During financial year 2004-05, the Honble High Court of Andhra Pradesh sanctioned the Scheme of Amalgamation with M/s. Zenotech Technologies Limited with effect from November 1st , 2003. The Company had issued 91,82,500 equity shares to erstwhile shareholders of M/s.

Zenotech Laboratories Pvt. Ltd. M/s, Credence Pharmaceuticals Limited and M/s, Hemarus Healthcare Private Limited were merged with the Company, on May 2, 2006 through Scheme of Amalgamation, effective from October 1, 2005.

15 generic chemical oncology products were launched by the Company in India. Besides, the Company launched its anesthesia range of products during 2006.In 2005-06, M/s, Credence Pharmaceuticals Limited and M/s, Hemarus Healthcare Private Limited got merged with the Company and the Scheme of Amalgamation became effective from October 1, 2005. Consequent to the consummation of the merger of Ranbaxy Laboratories Limited into SPIL on March 24, 2015, SPIL indirectly acquired 46.84 percent of the voting rights held by Ranbaxy in, and control over the Company and became Promoter of the Company along with Daiichi Sankyo Company Limited and resultant, the Open Offer concluded in August 2015.The Company started production from its newly commissioned Depot Injectable facility in FY 2019-20.

It renovated Biotech API manufacturing facility and the same was leased to Sun Pharmaceutical Industries Limited, for their R&D activities effective from July, 2021.